Before I ask a rosacea patient about their skincare routine or their treatment history, I ask about their rosacea. Specifically: which features are present, and which are currently active.
That answer shapes every treatment decision that follows.
Subtype classification: why it still matters
The four-subtype framework, erythematotelangiectatic (ETR), papulopustular (PPR), phymatous, and ocular, remains a useful clinical starting point even as guidelines have moved toward a phenotype-based approach that acknowledges how frequently these features overlap in the same patient.
The practical value of subtype thinking is procedural. Each subtype carries different risks in response to energy-based devices, chemical exfoliation, and topical actives. Understanding the subtype distribution in a patient, even when multiple features coexist, tells you what to consider and what to avoid.
Erythematotelangiectatic rosacea
ETR presents with central facial erythema, flushing, and visible telangiectasia. The skin is typically sensitive, reactive, and barrier-compromised. Patients in this group frequently have a long history of being told they have sensitive skin without anyone naming the underlying condition.
Intense pulsed light (IPL) and vascular lasers including pulsed dye laser have a well-established evidence base for background erythema and telangiectasia in ETR. Multiple sessions are typically needed. The outcomes are meaningful for patients whose daily erythema significantly affects quality of life.
Chemical exfoliation in ETR requires caution. Low-strength lactic acid or azelaic acid, applied when the skin is stable, can be well tolerated by some patients. High-strength glycolic or salicylic acid peels carry a significant flare risk. Even mild exfoliation in an actively flushing patient can worsen the presentation.
Barrier repair is the foundation of ETR management. Ceramide-containing moisturisers, mineral-filter SPF, and consistent avoidance of identified thermal and topical triggers should precede any procedural intervention and continue throughout it.
Papulopustular rosacea
PPR presents with the persistent central erythema of ETR alongside inflammatory papules and pustules. It is regularly misdiagnosed as acne. The key distinguishing features are the absence of comedones and the central facial distribution. Sebaceous hyperplasia may be present but open comedones are not a PPR feature.
In active PPR, energy-based devices including laser and IPL are contraindicated. Active inflammation is not the clinical setting for a thermal stimulus. Treating a flare with IPL risks worsening the inflammatory response and extending recovery. The condition must be documented as stable before any energy-based treatment is considered.
In stable PPR, with consistent absence of active papules over several weeks, IPL for background erythema and telangiectasia follows the same rationale as ETR. Stability, not just improvement, is the threshold.
The prescribable treatments for PPR include topical ivermectin, topical azelaic acid, topical metronidazole, and oral doxycycline at a low anti-inflammatory dose. These are distinct from acne antibiotic protocols. Aesthetic practitioners who are not prescribers need a documented referral pathway when a patient presents with active PPR requiring medical management. Supporting barrier function and trigger reduction remains within scope while the medical management is established.
Phymatous rosacea
Phymatous rosacea involves fibrosis and thickening of the skin, typically on the nose (rhinophyma) but also on the chin, forehead, cheeks, and ears. It is considerably more prevalent in male patients and tends to develop over years in undertreated presentations.
Significant rhinophyma is outside the scope of most aesthetic practice. CO2 laser resurfacing and surgical shaving have evidence for established rhinophyma. These are procedures for specialist dermatology or plastic surgery settings. When you encounter significant phymatous changes at consultation, document, photograph, and refer. Early-stage phymatous changes may benefit from the same anti-inflammatory topical management as PPR, and early referral is appropriate.
Ocular rosacea
Ocular rosacea causes eye irritation, dryness, a sensation of grittiness, and in more significant presentations, corneal damage. It frequently coexists with cutaneous rosacea. It is often underdiagnosed because patients attribute their eye symptoms to screen time, hay fever, or dry air.
Every rosacea consultation should include direct screening for ocular symptoms. Red, gritty, or light-sensitive eyes in a patient presenting with any rosacea subtype warrant ophthalmology referral. This is not optional. Unmanaged ocular rosacea carries real risk to vision. It is not an aesthetic practitioner concern to manage, but identifying it and referring is entirely within your clinical responsibility.
Rules that apply across all subtypes
Some principles apply regardless of which features are present. Avoid energy-based treatments during any active flare. Avoid fragranced products, harsh cleansers, and high-strength chemical actives in any symptomatic rosacea. Avoid extended sun exposure without broad-spectrum SPF. Before any aesthetic procedure, confirm the condition is stable and document it as such.
Rosacea is a chronic relapsing condition. The treatment plan covers what you do in clinic, what you document between visits, what you communicate to the patient about triggers and warning signs, and what happens if the condition flares after a procedure. Consent for any rosacea treatment should include a clear discussion of that possibility.
Rosacea Beyond Redness at aestheticsunlocked.co.uk/courses/rosacea-beyond-redness covers the full subtype and phenotype framework, procedure suitability by presentation, trigger mapping across all subtypes, and the evidence base for treatment. It is the clinical reference built for UK aesthetic practitioners. The course is £150 with lifetime access.